An old COVID-19 variant called A.30—which is exceedingly rare—“efficiently evades” antibodies induced by the Pfizer-BioNTech and AstraZeneca vaccines, according to a team of scientists in Germany.
Only five cases of the A.30 variant have been reported so far worldwide, according to the COVID-19 variant tracking network GISAID. Three of these were in Angola, and one case was detected in both the United Kingdom and Sweden.
It hasn’t been listed by the World Health Organization (WHO) as a variant of interest or concern, likely due to its low prevalence.
Researchers from Göttingen, Germany, analyzed the variant that was first detected in several patients in Angola and Sweden in the spring, which “likely originated in Tanzania.” They compared it to the Beta and Eta COVID-19 variants.
The A.30 variant “enters certain cell lines with increased efficiency and evades antibody-mediated neutralization,” the team found.
“Collectively, our results suggest that the SARS-CoV-2 variant A.30 can evade control by vaccine-induced antibodies and might show an increased capacity to enter cells in a cathepsin L-dependent manner, which might particularly aid in the extrapulmonary spread,” the scientists wrote in their study.
“Needs watching,” he added.
Other experts however have pointed out the A.30 variant’s low prevalence, coupled with the fact that the last recorded cases of the rare variant were between May and June this year.
The researchers however note that a potential spread of the A.30 variant in the future “warrants close monitoring and rapid installment of countermeasures.”
The Epoch Times has reached out to the lead author of the study, Markus Hoffmann, for additional comment.